DE68923878T2 - Rekombinante techniken zur herstellung neuer natriuretischer und gefässerweiternder peptide. - Google Patents

Rekombinante techniken zur herstellung neuer natriuretischer und gefässerweiternder peptide.

Info

Publication number
DE68923878T2
DE68923878T2 DE68923878T DE68923878T DE68923878T2 DE 68923878 T2 DE68923878 T2 DE 68923878T2 DE 68923878 T DE68923878 T DE 68923878T DE 68923878 T DE68923878 T DE 68923878T DE 68923878 T2 DE68923878 T2 DE 68923878T2
Authority
DE
Germany
Prior art keywords
entry
row
gly
arg
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68923878T
Other languages
English (en)
Other versions
DE68923878D1 (de
Inventor
J Seilhamer
John Lewicki
Robert Scarborough
J Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios Nova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68923878(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scios Nova Inc filed Critical Scios Nova Inc
Application granted granted Critical
Publication of DE68923878D1 publication Critical patent/DE68923878D1/de
Publication of DE68923878T2 publication Critical patent/DE68923878T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C07K14/582—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
DE68923878T 1988-05-31 1989-05-31 Rekombinante techniken zur herstellung neuer natriuretischer und gefässerweiternder peptide. Expired - Lifetime DE68923878T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20038388A 1988-05-31 1988-05-31
US20647088A 1988-06-14 1988-06-14
US29988089A 1989-01-19 1989-01-19
PCT/US1989/002373 WO1989012069A1 (en) 1988-05-31 1989-05-31 Recombinant techniques for production of novel natriuretic and vasodilator peptides

Publications (2)

Publication Number Publication Date
DE68923878D1 DE68923878D1 (de) 1995-09-21
DE68923878T2 true DE68923878T2 (de) 1995-12-21

Family

ID=27394150

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68923878T Expired - Lifetime DE68923878T2 (de) 1988-05-31 1989-05-31 Rekombinante techniken zur herstellung neuer natriuretischer und gefässerweiternder peptide.

Country Status (9)

Country Link
US (7) US5674710A (de)
EP (1) EP0418308B1 (de)
JP (1) JP2511160B2 (de)
AT (1) ATE126522T1 (de)
AU (1) AU3768189A (de)
CA (1) CA1339210C (de)
DE (1) DE68923878T2 (de)
IE (1) IE68889B1 (de)
WO (1) WO1989012069A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
JPH02222683A (ja) * 1989-02-22 1990-09-05 Dai Ichi Seiyaku Co Ltd 新規ｄｎａ
JP2883903B2 (ja) * 1989-03-10 1999-04-19 塩野義製薬株式会社 新規生理活性ペプチド及びその用途
US20020086843A1 (en) * 1989-03-01 2002-07-04 Daiichi Pure Chemicals Co., Ltd. Physiologically active polypeptide and DNA
DE69020755T3 (de) * 1989-03-01 2000-03-02 Shionogi & Co Physiologisch aktives Polypeptid und DNA.
US7211380B1 (en) 1989-03-01 2007-05-01 Shionogi & Co., Ltd. Physiologically active polypeptide and DNA
JP3160276B2 (ja) * 1989-03-01 2001-04-25 塩野義製薬株式会社 新規ｃＤＮＡフラグメント
JP3264439B2 (ja) * 1989-03-10 2002-03-11 塩野義製薬株式会社 新規生理活性ペプチド及びその用途
JP3026354B2 (ja) * 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
JP2809533B2 (ja) * 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US6028055A (en) * 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
JP3025672B2 (ja) * 1998-05-14 2000-03-27 塩野義製薬株式会社 新規生理活性ペプチド及びその用途
AU758562B2 (en) * 1999-01-29 2003-03-27 Roche Diagnostics Gmbh Method of identifying N-terminal proBNP
WO2000071576A2 (en) * 1999-05-24 2000-11-30 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
JP3346764B2 (ja) * 2000-12-05 2002-11-18 塩野義製薬株式会社 新規ｃＤＮＡフラグメント
US20030199000A1 (en) * 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7608406B2 (en) * 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040219509A1 (en) * 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040209307A1 (en) * 2001-08-20 2004-10-21 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
AU2003268531A1 (en) * 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
US20060110359A1 (en) * 2002-09-06 2006-05-25 Juan Sanchez-Ramos Cellular delivery of natriuretic peptides
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US7135329B2 (en) * 2002-11-18 2006-11-14 Princeton Biomeditech Corporation Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
US7109023B2 (en) * 2002-11-18 2006-09-19 Princeton Biomeditech Corporation Immunossay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
EP1562990B1 (de) 2002-11-18 2010-07-21 Syn X Pharma, Inc. Polyklonaler-monoklonaler-elisa-assay zum nachweis von n-terminalem probnp
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
DE60331584D1 (de) 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
WO2004062555A2 (en) * 2003-01-13 2004-07-29 Gudrun Rappold-Hoerbrand Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
US7767419B2 (en) * 2003-02-04 2010-08-03 Nexus Dx, Inc. Calibrator for NT-proBNP immunoassay
US8796235B2 (en) * 2003-02-21 2014-08-05 University Of South Florida Methods for attenuating dengue virus infection
US20060177870A1 (en) * 2003-04-28 2006-08-10 Ciphergen Biosystems, Inc Immunoassays
DK1638443T3 (da) * 2003-06-20 2011-02-07 Mayo Foundation Isoformer af hjerne-natriuretisk peptid
US20070238676A1 (en) * 2003-12-04 2007-10-11 Mohapatra Shyam S Polynucleotides for Reducing Respiratory Syncytial Virus Gene Expression
US7332569B2 (en) * 2004-01-27 2008-02-19 Compugen Ltd. Brain natriuretic peptide spliced variant
US20080182299A1 (en) * 2004-01-27 2008-07-31 Compugent Ltd. Novel brain natriuretic peptide variants and methods of use thereof
EP1727556A2 (de) * 2004-02-17 2006-12-06 University Of South Florida Material und methoden zur behandlung von entzündlichen erkrankungen und zellproliferationsstörungen
EP3404102B1 (de) 2004-04-21 2021-08-11 Alexion Pharmaceuticals, Inc. Knochenfreisetzungskonjugate und verfahren zur verwendung davon zum zielen von proteinen auf knochen
AT500800B1 (de) * 2004-09-08 2008-07-15 Biomedica Medizinprodukte Gmbh Verfahren zur bestimmung von probnp
US20060051825A1 (en) * 2004-09-09 2006-03-09 Buechler Kenneth F Methods and compositions for measuring canine BNP and uses thereof
US20060084114A1 (en) * 2004-10-15 2006-04-20 Yeo Kiang-Tech J Method for detecting cardiac collateral formation
US20080207505A1 (en) * 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
MX2007009760A (es) 2005-02-11 2007-11-07 Amylin Pharmaceuticals Inc Polipeptidos del analogo e hibrido del peptido inhibidor gastrico con propiedades seleccionables.
US7731965B2 (en) 2005-02-17 2010-06-08 Abbott Lab Human ring specific BNP antibodies
US20060280645A1 (en) * 2005-06-02 2006-12-14 Scott Sellers Method for terminal sterilization of transdermal delivery devices
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
DE102005039608A1 (de) * 2005-08-19 2007-03-01 Ormecon Gmbh Zusammensetzung mit intrinsisch leitfähigem Polymer
WO2007041645A2 (en) * 2005-10-03 2007-04-12 Scios Inc. Oxidized human bnp
US7939069B2 (en) 2005-11-09 2011-05-10 Abbott Laboratories Human BNP immunospecific antibodies
JP5364378B2 (ja) 2005-11-09 2013-12-11 アボット・ラボラトリーズ ヒトｂｎｐ免疫特異的抗体
AU2007233123A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
WO2007115175A2 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
EP2051585A4 (de) * 2006-04-28 2010-06-02 Univ South Florida Materialien und verfahren zur unterdrückung von entzündungen durch hemmung des vorhof-rezeptors für natriuretische peptide
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
WO2007147074A2 (en) 2006-06-14 2007-12-21 Living Microsystems, Inc. Use of highly parallel snp genotyping for fetal diagnosis
WO2008021872A1 (en) 2006-08-08 2008-02-21 Mayo Foundation For Medical Education And Research Diuretic and natriuretic polypeptides
US20080064045A1 (en) 2006-09-07 2008-03-13 Huaiqin Wu Biomarker fragments for the detection of human BNP
CA2662851A1 (en) * 2006-09-13 2008-03-20 Ormecon Gmbh Article with a coating of electrically conductive polymer and precious/semiprecious metal and process for production thereof
EP2150811B1 (de) * 2007-05-08 2013-01-16 Abbott Laboratories Test für menschliches natriuretisches typ-b-peptid mit verminderter kreuzreaktivität mit anderen peptidformen
US8357656B2 (en) * 2007-09-15 2013-01-22 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-C agonists
AU2008338803B2 (en) * 2007-11-26 2015-02-05 Glaxosmithkline Biologicals S.A. Methods of generating alphavirus particles
US9482677B2 (en) * 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
CA2737643C (en) 2008-09-20 2020-10-06 Hei-Mun Fan Noninvasive diagnosis of fetal aneuploidy by sequencing
LT2393828T (lt) 2009-02-03 2017-01-25 Amunix Operating Inc. Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos
CN102596216B (zh) * 2009-08-27 2016-04-20 远藤京子 鼻炎治疗剂
US9274126B2 (en) * 2009-11-13 2016-03-01 Bg Medicine, Inc. Risk factors and prediction of myocardial infarction
DE102010032482A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe zur Beeinflussung der natriuretischen Peptid-Rezeptoren A und B und deren Verwendung
WO2012013597A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
EP2601531A1 (de) 2010-08-04 2013-06-12 IDEXX Laboratories, Inc. Nachweis von zersetzungsprodukten von hundespezifischem nt-probnp
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
EP2678002A2 (de) 2011-02-25 2014-01-01 Medtronic, Inc. Therapie für nierenerkrankungen und/oder herzinsuffizienz
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
AU2012262154B2 (en) 2011-05-31 2016-08-04 Idexx Laboratories, Inc. Detection of degradation products of feline NT-proBNP
WO2013032784A1 (en) 2011-08-30 2013-03-07 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
EP2750697A4 (de) 2011-09-02 2015-03-25 Medtronic Inc Chimäre natriuretische peptidzusammensetzungen und verfahren zu ihrer herstellung
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
US10449236B2 (en) 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
JPWO2016194855A1 (ja) * 2015-05-29 2018-06-07 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬、外用剤および化粧料
WO2017031114A1 (en) 2015-08-17 2017-02-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (de) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei kindern
EP3436020A4 (de) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei jugendlichen und erwachsenen
JP2019513711A (ja) 2016-04-01 2019-05-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
EP3464573A4 (de) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. Auswirkungen von metallen auf die herstellung von alkalischen phosphatasen
EP3500289A4 (de) 2016-08-18 2020-05-06 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von tracheobronchomalazie
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
EP3773684A1 (de) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Herstellung von glycoproteinen
KR20220131221A (ko) 2019-11-13 2022-09-27 아뮤닉스 파마슈티컬스, 인크. 바코드화된 xten 폴리펩티드 및 이의 조성물, 및 이의 제조 방법 및 사용 방법
US11419917B2 (en) 2020-04-07 2022-08-23 Drora Shevy Treatment for SARS-CoV-2 and other coronaviruses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572173B2 (en) * 1983-08-29 1988-05-05 Institut De Recherches Cliniques De Montreal Natriuretic factors
US4496544A (en) * 1983-11-10 1985-01-29 Washington University Atrial Peptides
US4557864A (en) * 1984-01-10 1985-12-10 Washington University Atrial peptides
US4508712A (en) * 1984-01-10 1985-04-02 Washington University Atrial peptide
US4618600A (en) * 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
WO1985004872A1 (en) * 1984-04-24 1985-11-07 The Salk Institute For Biological Studies Atrial peptide analogs
US4609725A (en) * 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
DE3509958A1 (de) * 1985-03-20 1986-09-25 Bayer Ag, 5090 Leverkusen Monoklonale antikoerper gegen atriale, natriuretische peptide vom menschen
EP0246795A3 (de) * 1986-05-20 1990-04-04 Advanced Peptide Development Limited Synthetische natriuretische Peptide
US4673285A (en) * 1986-05-23 1987-06-16 Xerox Corporation Optical scanning of duplex documents
JPS63107997A (ja) * 1986-09-18 1988-05-12 Mitsubishi Kasei Corp ペプチド
US4804650A (en) * 1986-10-28 1989-02-14 Biotechnology Research Associates, J.V. Analogs of atrial natriuretic peptides
JP2544929B2 (ja) 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
EP0418308A1 (de) 1991-03-27
US20030109430A1 (en) 2003-06-12
US6974861B2 (en) 2005-12-13
US5674710A (en) 1997-10-07
US5948761A (en) 1999-09-07
US20060160150A1 (en) 2006-07-20
DE68923878D1 (de) 1995-09-21
EP0418308B1 (de) 1995-08-16
AU3768189A (en) 1990-01-05
IE68889B1 (en) 1996-07-24
WO1989012069A1 (en) 1989-12-14
ATE126522T1 (de) 1995-09-15
IE891792L (en) 1989-11-30
US20060030004A1 (en) 2006-02-09
US7179790B2 (en) 2007-02-20
US6897030B2 (en) 2005-05-24
JPH03505280A (ja) 1991-11-21
JP2511160B2 (ja) 1996-06-26
US20040002458A1 (en) 2004-01-01
US6586396B1 (en) 2003-07-01
CA1339210C (en) 1997-08-05
EP0418308A4 (en) 1991-11-13

Similar Documents

Publication Publication Date Title
DE68923878D1 (de) Rekombinante techniken zur herstellung neuer natriuretischer und gefässerweiternder peptide.
Goodman et al. Identification and location of brain protein 4.1
Gospodarowicz et al. Isolation of brain fibroblast growth factor by heparin-Sepharose affinity chromatography: identity with pituitary fibroblast growth factor.
US7361738B2 (en) Megakaryocyte stimulating factors
EP0506757B2 (de) Rekombinanter abkömmling des menschlichen faktors iii
DE69433301T2 (de) Methoden zur erhöhung der biologischen aktivität von chemokinen
KR100393508B1 (ko) 인간 인터루킨 4의 안타고니스트 또는 부분적 아고니스트로서의 신규hIL-4 변이단백질
RU2009130434A (ru) Рекомбинантные молекулы лубрицина и их использование
RU2007110981A (ru) Урокортин iii и его использование
DE170917T1 (de) Neues derivat des humangammainterferon-polypeptids.
Lustbader et al. Characterization of the expression products of recombinant human choriogonadotropin and subunits.
ATE195344T1 (de) Gereinigtes interleukin-1 und für interleukin-1 kodierende dns und deren herstellung, solche dns enthaltende vektoren und deren herstellung und verwendung zum transformieren von wirten, die die expression von interleukin-1 zulassen
DE69120626D1 (de) Polypeptid
EP0652903B1 (de) Neues menschliches, rekombinantes interferon gamma
TW570801B (en) Osteoclastgenic inhibitory agent
US5756458A (en) Stabilized potent GRF analogs
Negro et al. Synthesis, purification, and characterization of human ciliary neuronotrophic factor from E. coli
Harper et al. Human class 1 heparin-binding growth factor: structure and homology to bovine acidic brain fibroblast growth factor
EP0306870A2 (de) Gamma-Interferon-Derivate, Herstellungsverfahren, Vektoren dafür und Arzneimittel daraus
EP0477217B1 (de) Stabilisierte, starke grf-analoga
US6121237A (en) Neutrophil stimulating peptides
EP0241136A2 (de) Humaner, Klasse 1 Heparin bindender, Wachstumsfaktor
RU2119800C1 (ru) Аналог пептида фактора гормона роста (фгр), способ стимулирования секреции гормона роста и композиция для стимулирования секреции
Nishimura et al. Role of leucine residues in the C‐terminal region of human interleukin‐6 in the biological activity
CA2026776A1 (en) Stabilized, potent grf analogs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition